These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 21420491)

  • 1. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
    Raman NV; Prasad AV; Ratnakar Reddy K
    J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicological overview of impurities in pharmaceutical products.
    Jacobson-Kram D; McGovern T
    Adv Drug Deliv Rev; 2007 Jan; 59(1):38-42. PubMed ID: 17188779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
    Humfrey CD
    Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product.
    Dow LK; Hansen MM; Pack BW; Page TJ; Baertschi SW
    J Pharm Sci; 2013 May; 102(5):1404-18. PubMed ID: 23436613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliminating pharmaceutical impurities: Recent advances in detection techniques.
    Liu DQ; Sun M; Wu L
    Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug impurities: problems and regulations.
    Pifferi G; Mannucci A
    Boll Chim Farm; 1999 Nov; 138(10):500-7. PubMed ID: 10765465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
    Liu DQ; Chen TK; McGuire MA; Kord AS
    J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
    Bercu JP; Hoffman WP; Lee C; Ness DK
    Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
    Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
    J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
    Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
    Snodin DJ; McCrossen SD
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impurities in drug substances and drug products: new approaches to quantification and qualification.
    Berridge JC
    J Pharm Biomed Anal; 1995 Dec; 14(1-2):7-12. PubMed ID: 8833961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
    Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
    Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
    Brusick DJ
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for the investigation and control of process-related impurities in drug substances.
    Argentine MD; Owens PK; Olsen BA
    Adv Drug Deliv Rev; 2007 Jan; 59(1):12-28. PubMed ID: 17189658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.